Prebiotic stachyose inhibits PRDX5 activity and castration-resistant prostate cancer development

By sjmartinez • August 22, 2024

Wang R, Pan Y, Zhang L, Wang J, Ni J, Ding Y, Wang S, Yin J, Ding L, Ran X, Fan S, Sun Q, Tan SY, Koeffler HP, Li J, Mi Y, Chen YQ. Prebiotic stachyose inhibits PRDX5 activity and castration-resistant prostate cancer development. Int J Biol Macromol. 2024 Aug 19:134844. doi: 10.1016/j.ijbiomac.2024.134844. Epub ahead of print. PMID: 39168191.

Tags: castration-resistant prostate cancer, Drug-tolerant persister, Hematology/Oncology, Nuclear factor erythroid 2-related factor 2, peroxiredoxin 5, Publications, stachyose, Stachyose caproate

Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials

Zhao S, Cheng Y, Wang Q, Li X, Liao J, Rodon J, Meng X, Luo Y, Chen Z, Wang W, Yi T, Li Y, Yin[...]

Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

García-Saenz JA, Spera G, Pollán M, Bermejo B, Ruiz-Borrego M, Chan A, Martín M, Guerrero-Zotano Á, Calvo L, Rodríguez-Lescure Á, Marín M, Chap L, Crown[...]

Omidubicel-onlv Transplantation for Hematologic Malignancies: Results of a Multicenter Expanded Access Program

Horwitz ME, Schiller GJ, Tsai SB, Rezvani AR, Maziarz RT, Goshen U, Levy S, Schwarzbach A, Mazor RD, Stiff PJ. Omidubicel-onlv Transplantation for Hematologic Malignancies:[...]